- če imate odprtino (fistulo) med požiralnikom in dihalnimi potmi,
http://www.emea.europa.eu/

- if you have an opening (fistula) between the oesophagus and the airways
http://www.emea.europa.eu/

- neobičajna povezava ali prehod, podoben cevi, med sapnikom in požiralnikom ali med
http://www.emea.europa.eu/

- an abnormal tube-like connection or passage between the windpipe and the gullet, or between
http://www.emea.europa.eu/

- ste v preteklosti imeli težave s požiralnikom (cevjo, ki povezuje usta z želodcem),
http://www.emea.europa.eu/

- you have had problems in the past with your oesophagus (the tube that connects your mouth to
http://www.emea.europa.eu/

Če ste kdaj imeli težave s požiralnikom (to je cev, ki vaša usta povezuje z želodcem).
http://www.emea.europa.eu/

- If you have ever had problems with your oesophagus (the tube connecting your mouth to your
http://www.emea.europa.eu/

Bolnikom je treba povedati, da neupoštevanje teh navodil lahko poveča tveganje za težave s požiralnikom.
http://www.emea.europa.eu/

Patients should be informed that the risk of oesophageal problems may increase if they do not follow these instructions.
http://www.emea.europa.eu/

Bolnikom je treba povedati, da neupoštevanje teh navodil lahko poveča tveganje za težave s požiralnikom.
http://www.emea.europa.eu/

Patients should be informed that failure to follow these instructions may increase their risk of oesophageal problems.
http://www.emea.europa.eu/

- če imate določene težave s požiralnikom (požiralnik je cev, ki povezuje usta in želodec), kot sta
http://www.emea.europa.eu/

- if you have certain problems with your gullet (oesophagus - the tube that connects your
http://www.emea.europa.eu/

Zdravilo PhotoBarr so proučevali v eni glavni študiji, ki je vključevala 208 bolnikov z Barrettovim požiralnikom z visoko stopnjo displazije.
http://www.emea.europa.eu/

PhotoBarr has been studied in one main study involving 208 patients who had Barrett ’ s oesophagus with high-grade dysplasia.
http://www.emea.europa.eu/

PhotoBarr se uporablja za odpravo displazije (celice z netipičnimi spremembami, ki povečujejo tveganje za razvoj raka) visoke stopnje pri bolnikih z Barrettovim požiralnikom.
http://www.emea.europa.eu/

PhotoBarr is used to remove high -grade dysplasia (cells with atypical changes that increase the risk of developing cancer) in patients with Barrett's oesophagus (gullet).
http://www.emea.europa.eu/

Težave s požiralnikom se lahko kažejo kot simptomi, ki vključujejo hudo bolečino v prsih, hudo bolečino pri požiranju hrane in/ ali pitju pijače, hudo slabost ali bruhanje.
http://www.emea.europa.eu/

Problems in your oesophagus might give you symptoms including: severe pain in the chest, severe pain after swallowing food and/or drink, severe nausea, or vomiting.
http://www.emea.europa.eu/

Redko se lahko pojavijo neželeni učinki kot so epileptični napad, glavobol, zmedenost, spremembe vida ali cevi podobna neobičajna povezava med sapnikom in prehodom v želodec (požiralnikom).
http://www.emea.europa.eu/

Rarely, such side effects as seizures (fits), headache, confusion, changes in vision, or an abnormal tube-like connection between the windpipe and the passage to the stomach (gullet), may occur.
http://www.emea.europa.eu/

Fotodinamično zdravljenje (PDT, photodynamic therapy) s PhotoBarrom je indicirano v primeru odprave displazije visoke stopnje (HGD, high- grade dysplasia) pri bolnikih z Barrettovim požiralnikom (BP).
http://www.emea.europa.eu/

Photodynamic therapy (PDT) with PhotoBarr is indicated for ablation of high-grade dysplasia (HGD) in patients with Barrett's Oesophagus (BO).
http://www.emea.europa.eu/

Zdravilo PhotoBarr se uporablja za fotodinamično zdravljenje (zdravljenje z uporabo svetlobe) za odpravo displazije visoke stopnje (nenormalnih celic z visokim tveganjem, da postanejo rakave) pri bolnikih z Barrettovim požiralnikom.
http://www.emea.europa.eu/

PhotoBarr is used in photodynamic therapy (treatment using light) for the ablation (destruction) of high-grade dysplasia (abnormal cells at high risk of turning into cancer) in patients with Barrett’ s oesophagus.
http://www.emea.europa.eu/

Ker je število bolnikov z Barretovim požiralnikom majhno, velja ta bolezen za redko, zato je bilo zdravilo PhotoBarr dne 6. marca 2002 določeno kot „ zdravilo sirota “ (zdravilo, ki se uporablja pri redkih boleznih).
http://www.emea.europa.eu/

Because the number of patients with Barrett’ s oesophagus is low, the disease is considered ‘ rare’, and PhotoBarr was designated an ‘ orphan medicine ’ (a medicine used in rare diseases) on 6 March 2002.
http://www.emea.europa.eu/

Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila PhotoBarr pri fotodinamičnem zdravljenju za odpravo displazije visoke stopnje pri bolnikih z Barrettovim požiralnikom večje od z njim povezanih tveganj.
http://www.emea.europa.eu/

The Committee for Medicinal Products for Human Use (CHMP) decided that PhotoBarr’ s benefits are greater than its risks when used in photodynamic therapy for the ablation of high-grade dysplasia in patients with Barrett’ s oesophagus.
http://www.emea.europa.eu/

Zdravila PhotoBarr ne smejo uporabljati osebe s porfirijo (nezmožnostjo razgradnje porfirinov), hudimi težavami z jetri ali ledvicami, varicami (razširjenimi žilami) požiralnika ali želodca, velikimi razjedami požiralnika, fistulami (nenormalnimi prehodi) med požiralnikom in trahejo (sapnikom) oziroma med požiralnikom in bronhiji (dihalnimi kanali v pljučih) ali sumom za poškodbo velikih krvnih žil.
http://www.emea.europa.eu/

PhotoBarr must not be used in patients with porphyria (an inability to break down porphyrins), severe problems with the liver or kidneys, varices (swollen veins) in the oesophagus or stomach, large ulcers in the oesophagus, fistulae (abnormal passageways) between the oesophagus and either the trachea (windpipe) or the bronchi (airways in the lungs), or suspected damage to major blood vessels.
http://www.emea.europa.eu/

(1) če ste alergični na (preobčutljivi za) natrijev alendronat trihidrat, holekalciferol ali katerokoli drugo sestavino, (2) če imate težave s požiralnikom (del prebavne cevi med žrelom in želodcem) kot je zoženo ali oteženo požiranje, (3) če ne morete stati ali pokončno sedeti vsaj 30 minut, (4) če vam je zdravnik povedal, da imate nizko vrednost kalcija v krvi.
http://www.emea.europa.eu/

Do not take FOSAVANCE (1) if you are allergic (hypersensitive) to alendronate sodium trihydrate, colecalciferol or any of the other ingredients, (2) if you have certain problems with your gullet (oesophagus - the tube that connects your mouth, with your stomach) such as narrowing or difficulty swallowing, (3) if you cannot stand or sit upright for at least 30 minutes, (4) if your doctor has told you that you have low blood calcium.
http://www.emea.europa.eu/

(1) če ste alergični na (preobčutljivi za) natrijev alendronat trihidrat, holekalciferol ali katerokoli drugo sestavino, (2) če imate težave s požiralnikom (del prebavne cevi med žrelom in želodcem) kot je zoženo ali oteženo požiranje, (3) če ne morete stati ali pokončno sedeti vsaj 30 minut, (4) če vam je zdravnik povedal, da imate nizko vrednost kalcija v krvi.
http://www.emea.europa.eu/

Do not take ADROVANCE (1) if you are allergic (hypersensitive) to alendronate sodium trihydrate, colecalciferol or any of the other ingredients, (2) if you have certain problems with your gullet (oesophagus - the tube that connects your mouth with your stomach) such as narrowing or difficulty swallowing, (3) if you cannot stand or sit upright for at least 30 minutes, (4) if your doctor has told you that you have low blood calcium.
http://www.emea.europa.eu/

Navodila za zdravstveno osebje za pripravo zdravila in ravnanje z njim ter izobraževalno gradivo − Izobraževalna orodja so namenjena zdravnikom za optimiziranje razmerja koristi in tveganj pri zdravljenju s porfirini. − Bolnikov se NE sme zdraviti s porfirini, če: o imajo resno okvaro jeter. o če imajo odprtino (fistulo) med požiralnikom in dihalnimi potmi. o če imajo razjedo (erozijo) velikih krvnih žil.
http://www.emea.europa.eu/

Prescriber guide and Prescriber slide kit − The educational tools are designed to aid physicians in optimising the benefit-risk ratio of porfimer treatment. − Patients should NOT be treated with porfimer if: o they have severe hepatic disease. o they have trachea or broncho-oesophageal fistulas. o they have suspected erosions of major blood vessels.
http://www.emea.europa.eu/